Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2026)

Xilio Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $16.5 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 57.49% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (down 57.49% YoY) and the FY2025 annual result came in at $20.6 million, up 7.13% from the prior year.
• Non-Current Deffered Revenue declined to $16.5 million in Q1 2026 per XLO's latest filing, from $20.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $38.7 million in Q1 2025 and troughed at $8.4 million in Q3 2024.
• A 3-year average of $20.6 million and a median of $19.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue surged 203.58% in 2025, then tumbled 57.49% in 2026.
• Over 3 years, Non-Current Deffered Revenue stood at $19.3 million in 2024, then gained by 7.13% to $20.6 million in 2025, then dropped by 20.19% to $16.5 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $16.5 million, $20.6 million, and $25.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.